Unresectable Colorectal Carcinoma Clinical Trials

14 clinical trials for Unresectable Colorectal Carcinoma across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial — RECRUITING · PHASE3
• Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers — RECRUITING · PHASE1
• LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia — RECRUITING
• M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial — ACTIVE_NOT_RECRUITING · PHASE1
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial — NOT_YET_RECRUITING · PHASE2
• TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study — COMPLETED · PHASE2
• STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma — WITHDRAWN · PHASE1
• Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial — NOT_YET_RECRUITING · PHASE3
• Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC) — WITHDRAWN · PHASE2
• Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer — OTHER · PHASE2
• Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations — OTHER · PHASE2
• Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer — WITHDRAWN · PHASE2

Refine this search